MAREZINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAREZINE is an injectable small-molecule drug approved by GSK in 1954 for an undisclosed indication. The specific mechanism of action and therapeutic class are not publicly detailed in available records. As a legacy product with nearly 70 years of market presence, it represents a mature pharmaceutical asset with historical clinical significance.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a consolidating team focused on optimization and transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MAREZINE currently shows zero linked job openings, reflecting its mature lifecycle stage and approaching LOE. Career growth and mobility on this product are limited; professionals should treat roles here as consolidation or transition positions rather than growth opportunities.
Brand ManagerField Sales Representative
Worked on MAREZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.